Abbie Celniker joined Third Rock in 2016 bringing thirty years of experience in R&D and senior leadership roles. Celniker focuses on the formation, development and strategy of their portfolio companies and has active leadership roles in the following:
- Board member and interim chief executive officer of Goldfinch Bio
- Former president and chief executive officer of Eleven Biotherapeutics
Prior to joining Third Rock, she served as president and CEO of Eleven Biotherapeutics since 2011. Previously, Celniker was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion's executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals (now Takeda) and the vice president of protein technologies of the Wyeth Research facilities. Abbie Celniker is a member of the MassBio board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D.
Abbie Celniker has a B.A. in biology from the University of California, San Diego, and a Ph.D. in molecular biology from the University of Arizona.